Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC — Stella

Home/Premenopausal Breast Cancer/Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

View on ClinicalTrials.gov

Recruiting

Back to Premenopausal Breast Cancer trials

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Taiwan

Department of Oncology, National Taiwan University Hospital, Taipei

Key details

Phase

Safety & dosing

Sponsor

National Taiwan University Hospital

Enrollment target

~42 participants

Started

January 2023

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

20 Years and older

Sex

Female only

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.